The National Cancer Institute canceled a $100 million study of a new generation of breast cancer drugs, citing concerns about the study's usefulness and the drugs' safety. The study was to evaluate aromatase inhibitors, but two other large studies already are under way and would provide answers before the government study was finished.

Related Summaries